Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral vs IV Methylprednisolone for MS Relapses
NCT00984984Phase 3Unknown
- Sponsor
- CHU Rennes
- Start
- Mar 2008
- Primary completion
- Jun 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylprednisolone injection in multiple sclerosis (MS) (2 arms), sponsored by CHU Rennes. Primary endpoint: Improvement in Kurtzke Functional System Scale at 28 days. Status: unknown.
02
Drugs
methylprednisolone injection
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00984984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00984984.